NCT05909332 - Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) | Biotech Hunter

Enrollment

548

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

May 30, 2029

Study Completion Date

May 30, 2031

Conditions

Breast CancerTriple Negative Breast Cancer

Interventions

DRUG

Antivascular therapy

BP102 (anti VEGFR)

DRUG

Chemotherapy

ddEC-P

Trial Locations (15)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

110002

RECRUITING

The First Hospital of China Medical University, Shenyang

110801

RECRUITING

Liaoning Cancer Hospital & Institute, Shenyang

200032

RECRUITING

Breast cancer institute of Fudan University Cancer Hospital, Shanghai

200233

RECRUITING

Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai

201204

RECRUITING

Shanghai First Maternity and Infant Hospital, Shanghai

225009

RECRUITING

Northern Jiangsu People's Hospital, Yangzhou

226006

RECRUITING

Affiliated Hospital of Nantong University, Nantong

350001

RECRUITING

Fujian Medical University Union Hospital, Fuzhou

400030

RECRUITING

Chongqing Cancer Hospital, Chongqing

510062

RECRUITING

Sun Yat-sen University Cancer Center, Guangdong

610041

RECRUITING

West China Hospital of Sichuan University, Chengdu

710061

RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an

Unknown

RECRUITING

Guangdong Academy of Medical Sciences Guangdong Provincial People's Hospital, Guangzhou

RECRUITING

Ningbo Medical Center Lihuili Hospital, Ningbo

All Listed Sponsors

lead

Fudan University

OTHER